Weekly nab-paclitaxel in metastatic breast cancer - Summary and results of an expert panel discussion

Breast Care

Volumn 7, Issue 2, 2012, Pages 137-143

  Jackisch, Christian ^a   Lück, Hans Joachim ^b   Untch, Michael ^c   Bischoff, Joachim ^d   Müller, Volkmar ^e   Schmidt, Marcus ^f   Thill, Marc ^g   Kiechle, Marion ^h  

^a Klinikum Offenbach GmbH   (Germany)

^b Gynäkologisch Onkologische Schwerpunktpraxis   (Germany)

^c Helios Klinikum   (Germany)

^d UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f JOHANNES GUTENBERG UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chemotherapy; Docetaxel; First line therapy; Metastatic breast cancer; nab Paclitaxel; Paclitaxel; Weekly

Indexed keywords

ANTHRACYCLINE; CORTICOSTEROID; PACLITAXEL; SERUM ALBUMIN;

BREAST CANCER; CLINICAL PRACTICE; DRUG EFFICACY; DRUG TRANSPORT; HUMAN; HYDROPHOBICITY; MEDICAL EXPERT; METASTASIS; PRIORITY JOURNAL; REVIEW;

EID: 84861403115     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000338273     Document Type: Review

References (24)

1. AGO: Guidelines Breast, version 2012.1D; www.ago-online.de .
2. Sparano JA, Wang M, Martino S, et al.: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:1663-1671.
3. Seidman AD, Berry D, Cirrincione C, et al.: Randomized phase II trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642-1649.
4. Authier N, Gillet JP, Fialip J, et al.: Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats. Neurotox Res 2001;3:563-564.
5. Ten Tije AJ, Verweij J, Loos WJ, Sparreboom A: Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet 2003;42:665-668.
6. Sparreboom A, van Zuylen L, Brouwer E, et al.: Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. Cancer Res 1999;59:1454-1457.
7. Hamad I, Moghimi SM, et al.: Critical issues in sitespecific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug. Expert Opin Drug Deli 2008;5:205-219.
8. Minshall RD, Tiruppathi C, Vogel SM, et al.: Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function Histochem Cell Biol 2002;117:105-112.
9. Gradishar W, Tjulandin S, Davidson N, et al.: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-7803.
10. Gradishar W, Krasnojon D, Cheporov S, et al.: Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611-3619.
11. Gradishar WJ, Krasnojon D, Cheporov S, et al.: Albumin-bound paclitaxel (ab-pac) versus docetaxel for first-line treatment of metastatic breast cancer (MBC): final overall survival (OS) analysis of a randomized phase II trial. ASCO Breast Cancer Symposium 2011;abstr 275.
12. Blum J, Savin M, Edelman G, et al.: Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Canc 2007;7:850-856.
13. Abraxane® prescribing information.
14. Brezden C, Cantin G, Younus J, et al.: An openlabel, phase II study of weekly nab-paclitaxel as first-line therapy for patients with metastatic breast cancer: safety update. J Clin Oncol 2010;28 (suppl 159):abstr 1127.
15. Somer BD, Schwartzberg LS, Arena F, Epperson A, Fu D, Fortner BV: Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC). ASCO Ann Meet Proc Part I, J Clin Oncol 2007;25:1053.
16. Roy V, LaPlant BR, Gross GG, et al.: Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009;20:449-453.
17. Danso M, Blum J, Robert N, et al.: Phase II of weekly nab-paclitaxel in combination with bevacizumab as first line treatment in metastatic breast cancer. J Clin Oncol 2008;26(suppl):abstr 1075.
18. Conlin A, Hudis C, Bach A, et al.: Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC). J Clin Oncol 2009;27 (suppl 15):abstr 1006.
19. Lobo C, Lopes G, Baez O, et al.: Final results of a phase II study of nab-paclitaxel bevacizumab and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010;123:427-435.
20. Northfelt DW, Dueck AC, Flynn TP, et al.: Phase II trial combining nab-paclitaxel (NP), gemcitabine (g), and bevacizumab (B) in patients with metastatic breast cancer (MBC): NCCTG N0735. J Clin Oncol 2011;29(suppl):abstr 1126.
21. Mirtsching B, Cosgriff T, Harker G, et al.: A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. Clin Breast Canc 2011;11:121-128.
22. Conlin A, Seidman A, Bach A, et al.: Randomized phase II trial of nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first line therapy for women with HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2010;10:281-287.
23. Mehta RS, Schubbert T, Kong K, et al.: Pathologic complete response (pCR) following weekly (wkly) paclitaxel (cremophor or albumin-bound) and carboplatin (TC) trastuzumab (H), bevacizumab (B) in patients (pts) with doxorubicin/ cyclophosphamide-resistant (AC-Res) and ACsensitive (AC-S) large and inflammatory breast cancer. ASCO Ann Meet Proc Part I, J Clin Oncol 2007;25(suppl):591.
24. Roubidoux A, Buzdar AU, Quinaux E, et al.: A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin Breast Canc 2010;10:81-86.